patients with repeated implantation failure and ANA positive
Conditions
Interventions
Hydroxychloroquine sulfate group:Hydroxychloroquine sulfate
Sponsors
peking university third hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Patients who failed to obtain clinical pregnancy after at least 2 fresh or freeze-thaw embryo transfer cycles and at least 2 high-quality cleavage embryos or 1 high-quality blastula each time 2. ANA titer >= 1:80 was detected by indirect immunofluorescence at least 4 weeks interval >=2 times; 3. IVF treatment was performed at the reproductive center for the second pregnancy.
Exclusion criteria
Exclusion criteria: 1. Abnormal anatomical structure of reproductive system, hydrosalpinx, adenomyosis of uterus, interwall fibroids with fibroids >4cm in diameter and submucosal fibroids; 2. Chromosomal abnormalities of both spouses or one spouse; 3. There are other definite autoimmune diseases; 4. Anti-phospholipid antibody [including aCL antibody (IgG, IgM, IgA, chemiluminescence assay), anti-ß2Gpi antibody (IgG, IgM, IgA, chemiluminescence assay), aPS/PT antibody (IgG, IgM, chemiluminescence assay), LA (coagulation assay)] positive; 5. Women who are currently receiving pharammine, Exel, supraline, Android, any corticosteroid hormone or immunosuppressant, such as prednisone, cyclosporine, and azathioprine, require a corresponding washout period before screening. Such as faammine (within 30 hours), Exai (within 42 hours), Suprillin (within 21 hours), Android (within 126 hours), glucocorticoid (within 18 hours); 6. Possible contraindications of hydroxychloroquine with fundus macular disease or visual field defect; 7. Known past allergy to hydroxychloroquine; 8. Endometrium <7mm before transplantation; 9. There are assisted reproductive technologies or/and medical contraindications to pregnancy and/or there are contraindications to assisted pregnancy; 10. Non-high-quality embryos (high-quality embryos are defined as: Grade I or II D3 cleavage stage embryos, blastocyst stage embryos 4BC or above) 11. ? the age of 40.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinicalpregnancy; | — |
Secondary
| Measure | Time frame |
|---|---|
| hCG positive rate;Early abortion rate;Sustained pregnancy rate; | — |
Countries
China
Contacts
Public ContactWang Haiyan
peking university third hospital
Outcome results
None listed